VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Learn more about Palatin Technologies, Inc.'s (PTN) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
Financial Summary
Share Statistics
PTN
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$22.7
$282.4
11%
Shares Out (Mil)
3.9
54.0
12%
Institutional Ownership
82.5%
93.1%
51%
Float (Mil)
1.5
42.2
4%
Beta
-0.11
0.94
4%
Avg Daily Volume (000s)
176
482
44%
Price Change (52-week)
41.1%
59.9%
77%
Growth
PTN
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
14.1%
na
Net Income (5yr)
5.0%
(10.1%)
47%
EPS (5yr)
23.1%
15.9%
73
Dividends (5yr)
na
0.0%
0%
Cash Flow (5yr)
(15.6%)
(15.6%)
48%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
2
2
2
Current EPS
($1.125)
($2.990)
($2.430)
Month Ago EPS
($1.125)
($2.990)
($2.430)
# Rev Up
0
0
0
# Rev Down
1
1
1
Three Months Ago EPS
($1.125)
($2.990)
($2.430)
Year/Year Chg
207.4%
(90.7%)
(89.5%)
Financials
PTN
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
$13
$37
10%
Net Income (TTM) (Mil)
($6)
($43)
32%
EPS (TTM)
($3.044)
($1.500)
11%
Operating Cash Flow (TTM) (Mil)
($15)
($31)
17%
Net Cash Flow (TTM) (Mil)
na
$2
na
Long-Term Debt (Q1) (Mil)
$0
$4
10%
Enterprise Value (Q1) (Mil)
$12
$190
8%
Valuation
PTN
Industry Median
Percentile (All Stocks)
P/B
2.13
2.84
52%
P/E
na
20.2
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
1.0
na
Ratios
PTN
Industry Median
Percentile (All Stocks)
Gross Margin
4.3%
66.9%
6%
Net Margin
(48.5%)
(74.2%)
12%
ROA
(73.7%)
(47.7%)
8%
ROE
(297.2%)
(55.0%)
3%
Liabilities to Assets
19.9%
29.8%
13%
F-Score
2
3
7%
Palatin Technologies, Inc. did not pass any screens on 9/4/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors